Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.

Wang S, Higgins VJ, Aldrich-Wright JR, Wu MJ.

J Chem Biol. 2012 Apr;5(2):51-61. doi: 10.1007/s12154-011-0070-x. Epub 2011 Dec 6.

PMID:
23226166
[PubMed]
Free PMC Article
2.

Comparative analyses of cytotoxicity and molecular mechanisms between platinum metallointercalators and cisplatin.

Wang S, Wu MJ, Higgins VJ, Aldrich-Wright JR.

Metallomics. 2012 Aug;4(9):950-9. doi: 10.1039/c2mt20102j.

PMID:
22814756
[PubMed - indexed for MEDLINE]
3.

Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity?

Davis KJ, Carrall JA, Lai B, Aldrich-Wright JR, Ralph SF, Dillon CT.

Dalton Trans. 2012 Aug 21;41(31):9417-26. doi: 10.1039/c2dt30217a. Epub 2012 Jun 28.

PMID:
22740039
[PubMed - indexed for MEDLINE]
4.

Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Moretto J, Chauffert B, Ghiringhelli F, Aldrich-Wright JR, Bouyer F.

Invest New Drugs. 2011 Dec;29(6):1164-76. doi: 10.1007/s10637-010-9461-z. Epub 2010 Jun 10.

PMID:
20535526
[PubMed - indexed for MEDLINE]
5.

The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum(II)-based metallointercalators.

Kemp S, Wheate NJ, Buck DP, Nikac M, Collins JG, Aldrich-Wright JR.

J Inorg Biochem. 2007 Jul;101(7):1049-58. Epub 2007 May 4.

PMID:
17544512
[PubMed - indexed for MEDLINE]
6.

The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells.

Garbutcheon-Singh KB, Myers S, Harper BW, Ng NS, Dong Q, Xie C, Aldrich-Wright JR.

Metallomics. 2013 Aug;5(8):1061-7. doi: 10.1039/c3mt00023k.

PMID:
23784536
[PubMed - indexed for MEDLINE]
7.

Substituted beta-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators.

Krause-Heuer AM, Wheate NJ, Tilby MJ, Pearson DG, Ottley CJ, Aldrich-Wright JR.

Inorg Chem. 2008 Aug 4;47(15):6880-8. doi: 10.1021/ic800467c. Epub 2008 Jul 2.

PMID:
18597414
[PubMed - indexed for MEDLINE]
8.

Degradation of bidentate-coordinated platinum(II)-based DNA intercalators by reduced L-glutathione.

Kemp S, Wheate NJ, Pisani MJ, Aldrich-Wright JR.

J Med Chem. 2008 May 8;51(9):2787-94. doi: 10.1021/jm7016072. Epub 2008 Apr 16.

PMID:
18412325
[PubMed - indexed for MEDLINE]
9.

Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.

Krause-Heuer AM, Grünert R, Kühne S, Buczkowska M, Wheate NJ, Le Pevelen DD, Boag LR, Fisher DM, Kasparkova J, Malina J, Bednarski PJ, Brabec V, Aldrich-Wright JR.

J Med Chem. 2009 Sep 10;52(17):5474-84. doi: 10.1021/jm9007104.

PMID:
19658404
[PubMed - indexed for MEDLINE]
10.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
[PubMed - indexed for MEDLINE]
11.
12.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR.

Cancer Res. 1992 Apr 1;52(7):1710-6.

PMID:
1312897
[PubMed - indexed for MEDLINE]
Free Article
13.

Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.

Farrell N.

Cancer Invest. 1993;11(5):578-89. Review.

PMID:
8402226
[PubMed - indexed for MEDLINE]
14.

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.

Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.

Cancer Chemother Pharmacol. 1997;39(3):245-53.

PMID:
8996528
[PubMed - indexed for MEDLINE]
15.

Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.

Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.

Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.

PMID:
18571892
[PubMed - indexed for MEDLINE]
16.
17.

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.

Br J Cancer. 1991 Aug;64(2):215-20.

PMID:
1892748
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.

Lin X, Okuda T, Holzer A, Howell SB.

Mol Pharmacol. 2002 Nov;62(5):1154-9. Erratum in: Mol Pharmacol. 2003 Apr;63(4):957.

PMID:
12391279
[PubMed - indexed for MEDLINE]
Free Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk